ADMA Biologics, Inc. (ADMA)Healthcare | Biotechnology | Ramsey, United States | NasdaqGM
10.73 USD
+0.39
(3.772%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 7:42 a.m. EDT
The investment case for ADMA Biologics is currently fractured by legal overhangs and a lack of shareholder protection mechanisms. While the underlying business shows signs of recovery—evidenced by a 116% gain over the last nine years and robust profitability metrics like a 42% operating margin—the stock is trapped in a 'value trap' scenario. The market is pricing in significant downside risk due to pending class-action lawsuits, which is confirmed by the heavy put buying and the looming August 2026 deadline mentioned in recent headlines. This legal uncertainty creates a ceiling on the stock's ability to rally despite its strong fundamentals. Furthermore, the absence of any dividend history eliminates income appeal, leaving investors entirely exposed to capital appreciation risks in a volatile biotech sector. The short-term outlook remains neutral-to-bearish due to this legal drag, while the long-term potential is capped until the litigation clouds lift. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.038442 |
| AutoETS | 0.038443 |
| AutoTheta | 0.041458 |
| MSTL | 0.046998 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 2.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.989 |
| Excess Kurtosis | -0.09 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 49.935 |
| Revenue per Share | 2.178 |
| Market Cap | 2,403,355,392 |
| Trailing P/E | 15.33 |
| Forward P/E | 11.37 |
| Beta | 0.69 |
| Profit Margins | 32.98% |
| Website | https://www.admabiologics.com |
As of Oct. 10, 2026, 7:42 a.m. EDT: Speculators are positioning defensively with heavy out-of-the-money put volume and open interest, particularly at strikes significantly below the current price (e.g., $6.00 and $8.00 expiring Nov 2026), suggesting a fear of a sharp decline. Conversely, call activity is concentrated near the money and slightly out-of-the-money, with notable open interest walls at distant strikes ($27.00, $32.00) indicating speculative hopes for a massive rally, though these are outweighed by the defensive put positioning. Implied volatility is elevated on near-term puts, reflecting uncertainty around upcoming litigation deadlines and earnings.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.2527855 |
| Address1 | 465 State Route 17 |
| All Time High | 25.67 |
| All Time Low | 1.01 |
| Ask | 11.52 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 2,922,170 |
| Average Daily Volume3 Month | 2,678,668 |
| Average Volume | 2,678,668 |
| Average Volume10Days | 2,922,170 |
| Beta | 0.694 |
| Bid | 6.44 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 1.811 |
| City | Ramsey |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.73 |
| Current Ratio | 6.972 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 10.905 |
| Day Low | 10.49 |
| Debt To Equity | 49.935 |
| Display Name | ADMA Biologics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,961,800 |
| Earnings Call Timestamp Start | 1,785,961,800 |
| Earnings Growth | 0.143 |
| Earnings Quarterly Growth | 0.105 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | 224,192,992 |
| Ebitda Margins | 0.43764 |
| Enterprise To Ebitda | 11.023 |
| Enterprise To Revenue | 4.824 |
| Enterprise Value | 2,471,174,656 |
| Eps Current Year | 0.79667 |
| Eps Forward | 0.94333 |
| Eps Trailing Twelve Months | 0.7 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 201 478 5553 |
| Fifty Day Average | 9.6926 |
| Fifty Day Average Change | 1.0373993 |
| Fifty Day Average Change Percent | 0.10703003 |
| Fifty Two Week Change Percent | -25.278551 |
| Fifty Two Week High | 20.458 |
| Fifty Two Week High Change | -9.728001 |
| Fifty Two Week High Change Percent | -0.47551084 |
| Fifty Two Week Low | 7.21 |
| Fifty Two Week Low Change | 3.5199995 |
| Fifty Two Week Low Change Percent | 0.48821074 |
| Fifty Two Week Range | 7.21 - 20.458 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,382,016,600,000 |
| Float Shares | 219,657,296 |
| Forward Eps | 0.94333 |
| Forward P E | 11.3745985 |
| Free Cashflow | 54,755,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 640 |
| Fullday Change | 0.05000019 |
| Fullday Change Percent | 0.46598503 |
| Fullday Price | 10.78 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.64705 |
| Gross Profits | 331,468,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01969 |
| Held Percent Institutions | 0.92763 |
| Implied Shares Outstanding | 223,984,680 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. |
| Long Name | ADMA Biologics, Inc. |
| Market | us_market |
| Market Cap | 2,403,355,392 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_51119246 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 168,958,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,170,411,549 |
| Number Of Analyst Opinions | 4 |
| Open | 10.6 |
| Operating Cashflow | 136,720,000 |
| Operating Margins | 0.42159998 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 201 478 5552 |
| Pre Market Change | 0.05000019 |
| Pre Market Change Percent | 0.46598503 |
| Pre Market Price | 10.78 |
| Pre Market Time | 1,792,153,120 |
| Previous Close | 10.34 |
| Price Eps Current Year | 13.468562 |
| Price Hint | 2 |
| Price To Book | 5.924903 |
| Price To Sales Trailing12 Months | 4.6915336 |
| Profit Margins | 0.32981998 |
| Quick Ratio | 3.62 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.75 |
| Region | US |
| Regular Market Change | 0.389999 |
| Regular Market Change Percent | 3.77175 |
| Regular Market Day High | 10.905 |
| Regular Market Day Low | 10.49 |
| Regular Market Day Range | 10.49 - 10.905 |
| Regular Market Open | 10.6 |
| Regular Market Previous Close | 10.34 |
| Regular Market Price | 10.73 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 2,766,292 |
| Return On Assets | 0.2178 |
| Return On Equity | 0.41897 |
| Revenue Growth | 0.02 |
| Revenue Per Share | 2.178 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 223,984,680 |
| Shares Percent Shares Out | 0.092 |
| Shares Short | 20,597,867 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 23,870,475 |
| Short Name | ADMA Biologics Inc |
| Short Percent Of Float | 0.113299996 |
| Short Ratio | 7.0 |
| Source Interval | 15 |
| State | NJ |
| Symbol | ADMA |
| Target High Price | 21.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 17.0 |
| Target Median Price | 17.5 |
| Total Cash | 136,020,000 |
| Total Cash Per Share | 0.607 |
| Total Debt | 203,839,008 |
| Total Revenue | 512,275,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.7 |
| Trailing P E | 15.328571 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 11.3447 |
| Two Hundred Day Average Change | -0.6147003 |
| Two Hundred Day Average Change Percent | -0.05418392 |
| Type Disp | Equity |
| Volume | 2,766,292 |
| Website | https://www.admabiologics.com |
| Zip | 7,446 |